** Materials for this course will be release on 06/24/2020 **

Infectious Diseases Pharmacy Specialty Review Course for Recertification, Workbook Chapters + RECERT Assessment Package (Cert # L209197)

Teaser: This online course will help you earn BCIDP recertification credit. With this course, get comprehensive, practical guidance, with a variety of complex cases, including references for further study.

Tag: Certifications; Infectious Diseases

ACPE Numbers: Various – see listing below
Pre-Sale Date: 05/27/2020
Content Release Date: 06/24/2020
Expiration Date: 06/22/2021
Activity Type: Application-based
CE Credits: 25.00 (BPS and ACPE)
Activity Fee: $475 (ASHP member); $675 (non-member)

Accreditation for Pharmacists
The American Society of Health-System Pharmacists and the American College of Clinical Pharmacy are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Target Audience
These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in infectious diseases pharmacy.

Activity Overview
This course is intended for BCIDPs in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS) to provide an overview of recent standards and guidelines that specialists should be familiar with in practice. The course uses a case-based approach to discuss patient care issues. In this series, faculty will:

- Review pertinent clinical topics and practice skills
- List valuable resources for further self-study

This online course consists of 15 activities (see table below) and provides up to 25 hours of continuing pharmacy education credit and/or recertification credit.

Recertification Credit*
Board certified pharmacists are eligible to receive up to 25 hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the
** Materials for this course will be release on 06/24/2020 **

Online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

This course is not intended for those preparing to take the BPS Infectious Diseases Pharmacy Specialty Examination for Certification. To prepare for the examination, please see courses here: [http://elearning.ashp.org/catalog/ID-review](http://elearning.ashp.org/catalog/ID-review)

These activities are part of the ASHP and ACCP professional development program for BCIDP recertification approved by the BPS.

* Please note: Review Course for Recertification may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle.

<table>
<thead>
<tr>
<th>Learning Activity</th>
<th>ACPE Number</th>
<th>Credit Hours</th>
<th>*Assessment Pass Point</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infectious Diseases Pharmacy Specialty Review Course: Antimicrobial Stewardship</td>
<td>0204-9999-20-946-H01-P</td>
<td>1.50</td>
<td>TBD</td>
</tr>
<tr>
<td>Infectious Diseases Pharmacy Specialty Review Course: Upper Respiratory Tract Infections</td>
<td>0204-9999-20-947-H01-P</td>
<td>2.00</td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases Pharmacy Specialty Review Course: Lower Respiratory Tract Infections</td>
<td>0204-9999-20-948-H01-P</td>
<td>1.50</td>
<td></td>
</tr>
<tr>
<td><strong>Group 1 Assessment</strong></td>
<td></td>
<td><strong>5.00</strong></td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases Pharmacy Specialty Review Course: HIV Infection and AIDS</td>
<td>0204-9999-20-949-H02-P</td>
<td>2.00</td>
<td>TBD</td>
</tr>
<tr>
<td>Infectious Diseases Pharmacy Specialty Review Course: Infections of Reproductive Organs and Sexually-Transmitted Diseases</td>
<td>0204-9999-20-950-H01-P</td>
<td>1.50</td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases Pharmacy Specialty Review Course: Opportunistic Infections in Immunocompromised Patients</td>
<td>0204-9999-20-951-H01-P</td>
<td>1.50</td>
<td></td>
</tr>
<tr>
<td><strong>Group 2 Assessment</strong></td>
<td></td>
<td><strong>5.00</strong></td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases Pharmacy Specialty Review Course: Gastrointestinal and Intra-abdominal Infections</td>
<td>0204-9999-20-952-H01-P</td>
<td>1.50</td>
<td>TBD</td>
</tr>
<tr>
<td>Infectious Diseases Pharmacy Specialty Review Course: Viral Hepatitis</td>
<td>0204-9999-20-953-H01-P</td>
<td>2.00</td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases Pharmacy Specialty Review Course: Tuberculosis and Other Mycobacterial Infections</td>
<td>0204-9999-20-954-H01-P</td>
<td>1.50</td>
<td></td>
</tr>
<tr>
<td><strong>Group 3 Assessment</strong></td>
<td></td>
<td><strong>5.00</strong></td>
<td></td>
</tr>
</tbody>
</table>
**Materials for this course will be release on 06/24/2020**

<table>
<thead>
<tr>
<th>Course</th>
<th>ACPE Number</th>
<th>CPE Credits</th>
<th>TBD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infectious Diseases Pharmacy Specialty Review Course: Cardiovascular Infections</td>
<td>0204-9999-20-955-H01-P</td>
<td>1.50</td>
<td>TBD</td>
</tr>
<tr>
<td>Infectious Diseases Pharmacy Specialty Review Course: Urinary Tract Infections</td>
<td>0204-9999-20-956-H01-P</td>
<td>1.50</td>
<td>TBD</td>
</tr>
<tr>
<td>Statistics, Evidence-based Medicine, and Research Design</td>
<td>0204-9999-20-908-H04-P</td>
<td>2.00</td>
<td></td>
</tr>
<tr>
<td>Group 4 Assessment</td>
<td></td>
<td>5.00</td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases Pharmacy Specialty Review Course: Bone and Joint Infections and Skin and Soft Tissue Infections</td>
<td>0204-9999-20-958-H01-P</td>
<td>1.50</td>
<td>TBD</td>
</tr>
<tr>
<td>Infectious Diseases Pharmacy Specialty Review Course: Central Nervous System Infections</td>
<td>0204-9999-20-959-H01-P</td>
<td>1.50</td>
<td>TBD</td>
</tr>
<tr>
<td>Infectious Diseases Pharmacy Specialty Review Course: Clinical Microbiology</td>
<td>0204-9999-20-960-H01-P</td>
<td>2.00</td>
<td></td>
</tr>
<tr>
<td>Group 5 Assessment</td>
<td></td>
<td>5.00</td>
<td></td>
</tr>
</tbody>
</table>

**Learning Objectives**

After participating in this CPE activity, learners should be able to:

**Antimicrobial Stewardship**

ACPE Number: 0204-9999-20-946-H01-P

- Outline components of an effective stewardship program.
- Select appropriate resources; relevant accreditation, legal, regulatory, and safety requirements; and quality metrics related to infectious diseases.
- Evaluate institutional treatment policies and pathways for compliance with antimicrobial stewardship guidelines, surveillance data, and best available evidence.
- Assess the effectiveness of infection prevention strategies.
- Identify metrics for evaluating the value of infectious diseases pharmacy services.

**Upper Respiratory Tract Infections**

ACPE Number: 0204-9999-20-947-H01-P

- Assess pharmacotherapies for upper respiratory tract infections.
- Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information, antibiogram data, and best available evidence.
- Recommend modifications of patient-specific treatment plans based on efficacy and adverse effects.
- Identify recommended immunizations and potential adverse effects.

**Lower Respiratory Tract Infections**

ACPE Number: 0204-9999-20-948-H01-P

- Assess pharmacotherapies for lower respiratory tract infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
- Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information, antibiogram data, and best available evidence.
** Materials for this course will be release on 06/24/2020 **

- Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
- Recommend the most appropriate modifications of patient-specific treatment plans based on efficacy, adverse effects, and follow-up assessment.
- Interpret biomedical literature with regard to study design and methodology, significance of reported data and conclusions, limitations, and applicability of study results to patients with lower respiratory tract infections.

HIV Infection and AIDS
0204-9999-20-949-H02-P

- Assess pharmacotherapies for HIV-infection and AIDS, including opportunistic infections.
- Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information, antibiogram data, and best available evidence.
- Identify recommended immunizations and screening guidelines for patients with HIV.
- Recommend modifications of patient-specific treatment plans based on efficacy, drug interactions, immunologic response, and adverse effects.
- Interpret signs, symptoms, and laboratory and other relevant diagnostic test results related to HIV infection.
- Evaluate a plan to facilitate transitions of care.

Infections of Reproductive Organs and Sexually Transmitted Diseases
0204-9999-20-950-H01-P

- Assess pharmacotherapies for infections of reproductive organs and sexually transmitted diseases.
- Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information, antibiogram data, and best available evidence.
- Identify recommended screening guidelines for sexually-transmitted diseases.
- Recommend modifications of patient-specific treatment plans based on efficacy, immunologic response, and adverse effects.
- Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
- Outline key considerations in effective patient and caregiver education and counseling techniques.

Opportunistic Infections in Immunocompromised Patients
0204-9999-20-951-H01-P

- Assess the advantages and disadvantages of pharmacotherapies for opportunistic infections in immunocompromised patients, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
- Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information and best available evidence.
- Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
- Recommend modifications of patient-specific treatment plans based on efficacy, immunologic response, and adverse effects.
- Identify preventative therapies in immunocompromised patients.
**Materials for this course will be release on 06/24/2020**

**Gastrointestinal and Intra-abdominal Infections**
0204-9999-20-952-H01-P

- Assess pharmacotherapies for gastrointestinal and intra-abdominal infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
- Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information, antibiogram data, and best available evidence.
- Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
- Recommend modifications of patient-specific treatment plans based on efficacy, immunologic response, and adverse effects.

**Viral Hepatitis**
0204-9999-20-953-H01-P

- Assess pharmacotherapies for viral hepatitis, including relevant pharmacology and spectrum of activity.
- Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information, virus and genotype, and best available evidence.
- Interpret signs, symptoms, laboratory and other relevant diagnostic test results.
- Recommend modifications of patient-specific treatment plans based on efficacy, adverse effects, and drug interactions.
- Outline key considerations in effective patient and caregiver education and counseling techniques.
- Identify screening guidelines and preventive therapies for viral hepatitis.

**Tuberculosis and Other Mycobacterial Infections**
0204-9999-20-954-H01-P

- Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information, antibiogram data, and best available evidence.
- Interpret signs, symptoms, laboratory and other relevant diagnostic test results.
- Recommend modifications of patient-specific treatment plans based on efficacy, adverse effects, and drug interactions.
- Outline key considerations in effective patient and caregiver education and counseling techniques.
- Identify screening guidelines and preventive therapies for tuberculosis and other mycobacterial infections.

**Cardiovascular Infections**
0204-9999-20-955-H01-P

- Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information, antibiogram data, and best available evidence.
- Identify drug-related problems associated with the therapeutic plan.
** Materials for this course will be release on 06/24/2020 **

- Recommend modifications of patient-specific pharmacotherapeutic plans based on efficacy and adverse effects.
- Interpret biomedical literature with regard to study design and methodology, significance of reported data and conclusions, limitations, and applicability of study results to patients with cardiovascular infections.

**Urinary Tract Infections**
0204-9999-20-956-H01-P
- Assess pharmacotherapies for urinary tract infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
- Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information, antibiogram data, and best available evidence.
- Interpret signs, symptoms, laboratory and other relevant diagnostic test results.
- Identify infectious diseases for which notification of the Centers for Disease Control and Prevention is required.

**Statistics, Evidence-based Medicine, and Research Design**
0204-9999-20-908-H04-P
- Evaluate quality and appropriateness, with specific attention to study design, statistical analysis, internal/external validity, source of bias/confounders, and quality of conclusions and interpretation of graphs.
- Explain why a statistical test is appropriate or not appropriate, based on the sample distribution, data type, and study design.
- Interpret clinical and statistical significance for results from commonly used statistical tests.
- Explain the strengths and limitations of different types of measures of central tendency (mean, median, and mode) and data spread (standard deviation, standard error of the mean, range, and interquartile range).
- Evaluate odds ratio, risk/incidence rate, relative risk, number needed to treat, number needed to harm, and other risk estimates.
- Determine whether the study applies to a specified patient population.

**Bone and Joint Infections and Skin and Soft Tissue Infections**
0204-9999-20-958-H01-P
- Assess the advantages and disadvantages of pharmacotherapies for bone and joint infections and skin and soft tissue infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
- Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information, antibiogram data, and best available evidence.
- Identify drug-related problems associated with the therapeutic plan.
- Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
Materials for this course will be release on 06/24/2020

- Recommend modifications of patient-specific pharmacotherapeutic plans based on efficacy and adverse effects.
- Describe the etiology, diagnosis, and treatment of acute bacterial osteomyelitis and septic arthritis in pediatric patients.

Central Nervous System Infections
0204-9999-20-959-H01-P
- Assess pharmacotherapies for central nervous system infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
- Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information, antibiogram data, and best available evidence.
- Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
- Identify preventive therapies for central nervous system infections.

Clinical Microbiology
0204-9999-20-960-H01-P
- Characterize the mechanisms of antimicrobial resistance among various pathogens.
- Identify basic microbiology laboratory procedures.
- Interpret laboratory and other diagnostic test results relevant to the diagnosis, management, and monitoring of patients with infectious diseases.
- Evaluate biomedical literature with regard to study design and methodology specific to infectious diseases.

Faculty

Samuel L. Aitken, Pharm.D., M.P.H., BCIDP
Clinical Pharmacy Specialist - Infectious Diseases
The University of Texas MD Anderson Cancer Center
Houston, TX

Melissa Badowski, Pharm.D., M.P.H., BCPS, AAHIVP, FCCP
Clinical Associate Professor
University of Illinois at Chicago, College of Pharmacy
Chicago, Illinois

Elizabeth A. Coyle, Pharm.D., BCPS, FCCM
Associate Dean for Academic Affairs/Clinical Professor
University of Houston College of Pharmacy
Houston, Texas
** Materials for this course will be release on 06/24/2020 **

Eric Egelund, Pharm.D., Ph.D., AAHIVE  
Clinical Assistant Professor  
University of Florida  
Jacksonville, Florida

Kevin W. Garey, Pharm.D., M.S., FASHP*  
Professor and Chair  
University of Houston  
Houston, Texas

Julie Harting, Pharm.D., BCIDP  
Associate Professor  
Sullivan University College of Pharmacy and Health Sciences  
Clinical Pharmacist Specialist, Infectious Disease  
University Hospital  
Louisville, Kentucky

Kayla R. Stover, Pharm.D., BCIDP, BCPS, FCCP, FIDSA*  
Associate Professor  
University of Mississippi School of Pharmacy  
Jackson, Mississippi

Angela Huang, Pharm.D., BCIDP  
Clinical Pharmacy Specialist, Infectious Diseases/Antimicrobial Stewardship  
HonorHealth John C. Lincoln Medical Center  
Phoenix, Arizona

Jerod Nagel, Pharm.D., BCIDP  
Team Lead, Infectious Diseases & Antimicrobial Stewardship  
University of Michigan Health System  
Ann Arbor, Michigan

J. Nicholas O'Donnell, Pharm.D., M.Sc., BCPS  
Assistant Professor  
Albany College of Pharmacy and Health Sciences  
Albany, New York

Natasha Pettit, Pharm.D., BCPS-AQ ID  
Infectious Diseases Clinical Pharmacy Specialist,  
University of Chicago Medicine  
Chicago, Illinois
**Materials for this course will be release on 06/24/2020**

Jason Schafer, Pharm.D., M.P.H., BCIDP, BCPS-AQ ID, AAHIVP*
Associate Professor
Department of Pharmacy Practice
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania

Juwon Yim, Pharm.D., M.P.H., BCPPS
Clinical Pharmacist Specialist
Children's Healthcare of Atlanta
Atlanta, Georgia

Marylee Worley, Pharm.D., BCIDP, BCPS
Assistant Professor
Nova Southeastern University College of Pharmacy
Fort Lauderdale, Florida

Evan Zasowski, Pharm.D., M.P.H., BCPS, BCIDP*
Assistant Professor
Touro University California College of Pharmacy
Vallejo, California

*Content matter experts

Reviewers
Kristi N. Hofer, Pharm.D.
Susan R. Dombrowski, M.S., RPh

Field Testers
TBD

Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP and ACCP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.
** Materials for this course will be release on 06/24/2020 **

All faculty and planners for ASHP and ACCP education activities are qualified and selected by ASHP and ACCP and required to disclose any relevant financial relationships with commercial interests. ASHP and ACCP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

Kevin W. Garey, Merck & Co., Research grant recipient  
Jason J. Schafer, Research Grant Recipient and Advisory Board, Merck and Research Grant Recipient, Gilead  
Samuel L. Aitken, Merck- Advisory board, Gram negative advisory panel

All other planners, presenters, reviewers, ASHP and ACCP staff and others with an opportunity to control content report no financial relationships relevant to this activity.

Methods and CE Requirements
Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity.

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

System Technical Requirements
Learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites.

View the minimum technical and system requirements for learning activities.

Development
These activities were developed by ASHP and ACCP.